Sirolimus Clinical Trials (44 Recruiting)

Showing 1–20 of 51 trials

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease

National Institute of Allergy and Infectious Diseases (NIAID)10 enrolled1 locationNCT06325709

Recruiting

Phase 1Phase 2

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

X-linked Myotubular Myopathy

Astellas Gene Therapies9 enrolled4 locationsNCT07052929

Recruiting

Phase 1Phase 2

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

National Cancer Institute (NCI)430 enrolled1 locationNCT05327023

Recruiting

Phase 2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sickle Cell Disease

University of Illinois at Chicago50 enrolled1 locationNCT03121001

Recruiting

Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies

National Cancer Institute (NCI)155 enrolled1 locationNCT07162038

Recruiting

Phase 4

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

Antiphospholipid (aPL)-PositiveThrombocytopaenia

Peking University First Hospital84 enrolled10 locationsNCT06722586

Recruiting

Phase 2

The Role of Sirolimus in Preventing Functional Decline in Older Adults

Aging

Irina Timofte10 enrolled1 locationNCT05237687

Recruiting

Phase 1Phase 2

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Non-Malignant Neoplasm

Fred Hutchinson Cancer Center40 enrolled1 locationNCT04083183

Recruiting

Phase 2Phase 3

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

Systemic Lupus ErythematosusImmune Thrombocytopenia

Chinese SLE Treatment And Research Group164 enrolled1 locationNCT07657793

Recruiting

Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more

National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839

Recruiting

Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation

National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418

Recruiting

Phase 1Phase 2

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Hematologic Neoplasms

National Cancer Institute (NCI)320 enrolled2 locationsNCT04959175

Recruiting

Phase 1

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Sickling Disorder Due to Hemoglobin S

Columbia University24 enrolled1 locationNCT07015684

Recruiting

Phase 1

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Multiple Myeloma

Christopher Strouse10 enrolled1 locationNCT07581704

Recruiting

Phase 2

Sirolimus Clinical Trials

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

The Role of Sirolimus in Preventing Functional Decline in Older Adults

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Allo HSCT for High Risk Hemoglobinopathies

Rapalog Pharmacology (RAP PAC) Study

Advancing Transplantation Outcomes in Children